Coulter Partners was very pleased to partner recently with CENTOGENE (Nasdaq: CNTG) to secure the appointment of Philip Lambert, PhD in Cambridge, MA as Chief Scientific Officer. With more than two decades of experience in the global drug discovery and pre-clinical development sectors, Philip will have the overall responsibility of driving scientific programs to align with the needs of pharmaceutical partners.
Daniela Osterholz, Head of Human Resources at CENTOGENE, commented: “We are extremely pleased to have Philip Lambert join CENTOGENE’s Executive Leadership Team, and the extensive experience and knowledge in the rare disease field he adds to the Company. Philip’s appointment and the further profiling of the leadership team marks a significant advancement to the Company’s pursuit to shorten the diagnostic odyssey and create treatment solutions for patients and their families. I would like to thank the team at Coulter Partners for their outstanding professional support in achieving this high caliber appointment.”
Philip joins CENTOGENE from Life Biosciences, a global company focused on extending the healthy lifespan of individuals by investigating eight biological pathways believed to increase longevity. He served as Senior Vice President of Discovery and Labs as well as Chief Operating Officer of two subsidiary companies, Selphagy Therapeutics and Spotlight Biosciences. Prior to Life Biosciences, Philip served as Scientific Partner and Head of Discovery at Charles River Laboratories, where he was responsible for establishing scientific credibility and delivering the business to client companies and venture capital firms. Philip also co-founded VivoPath, a preclinical screening company, offering clients discovery and development services for proof-of-concept testing. He holds a PhD in Neuropharmacology from Imperial College – University of London and a BSc in Pharmacology from the University of Liverpool.
CENTOGENE is a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. The Company’s goal is to bring rationality to treatment decisions and to accelerate the development of new orphan drugs by using our knowledge of the global rare disease market, including epidemiological and clinical data and innovative biomarkers. CENTOGENE has developed a global proprietary rare disease platform based on our real-world data repository with approximately 2.1 billion weighted data points from approximately 465,000 patients representing over 120 different countries as of September 30, 2019, or an average of over 500 data points per patient.
The Company’s platform includes epidemiologic, phenotypic, and genetic data that reflects a global population, and also a biobank of these patients’ blood samples. CENTOGENE believes this represents the only platform that comprehensively analyzes multi-level data to improve the understanding of rare hereditary diseases, which can aid in the identification of patients and improve our pharmaceutical partners’ ability to bring orphan drugs to the market. As of September 30, 2019, the Company collaborated with over 35 pharmaceutical partners for over 30 different rare diseases.
For more information about CENTOGENE, please visit www.centogene.com
LSX - European Lifestars Awards
14 November 2022
Top global hires for large-cap, mid-cap and public companies
07 June 2022
Top hires for VC & PE portfolio companies Q4-2021
25 January 2022
Top hires for VC & PE portfolio companies Q2-2021
27 July 2021